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Abstract 41 
Adenomatous Polyposis Coli (APC) is the most frequently mutated gene in colorectal 42 
cancer. APC negatively regulates the Wnt signaling pathway by promoting the 43 
degradation of b-catenin, but the extent to which APC exerts Wnt/b-catenin-independent 44 
tumor suppressive activity is unclear. To identify interaction partners and b-catenin-45 
independent targets of endogenous, full-length APC, we applied label-free and 46 
multiplexed TMT mass spectrometry. Affinity enrichment-mass spectrometry identified 47 
more than 150 previously unidentified APC interaction partners. Moreover, our global 48 
proteomic analysis revealed that roughly half of the protein expression changes that 49 
occur in response to APC loss are independent of b-catenin. Combining these two 50 
analyses, we identified Misshapen-like kinase 1 (MINK1) as a putative substrate of an 51 
APC-containing destruction complex. We validated the interaction between endogenous 52 
MINK1 and APC and further confirmed the negative – and b-catenin-independent –53 
regulation of MINK1 by APC. Increased Mink1/Msn levels were also observed in mouse 54 
intestinal tissue and Drosophila follicular cells expressing mutant Apc/APC when 55 
compared to wild-type tissue/cells. Collectively, our results highlight the extent and 56 
importance of Wnt-independent APC functions in epithelial biology and disease.  57 
Implications: The tumor suppressive function of APC - the most frequently mutated 58 
gene in colorectal cancer – is mainly attributed to its role in b-catenin/Wnt signaling. Our 59 
study substantially expands the list of APC interaction partners and reveals that 60 
approximately half of the changes in the cellular proteome induced by loss of APC 61 
function are mediated by b-catenin-independent mechanisms. 62 
 63 
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 64 
Introduction 65 
Mutations in Adenomatous Polyposis Coli (APC) are a frequent (> 80%) and early event 66 
in the development of sporadic colorectal cancer (1, 2). Germline mutations in APC also 67 
form the genetic basis of Familial Adenomatous Polyposis (FAP), an inherited form of 68 
the disease that is characterized by hundreds of colorectal polyps that progress to 69 
cancerous lesions if left untreated (3). This makes a comprehensive understanding of 70 
the normal interactions and functions of APC crucial for effectively targeting APC mutant 71 
cells. 72 
The tumor suppressive function of APC has been mainly attributed to its role in 73 
Wnt signaling. In conjunction with Axin, APC acts as a scaffold for the b-catenin 74 
destruction complex, thereby limiting the transcription of pro-proliferative b-catenin 75 
target genes in the absence of Wnt ligands (4). The vast majority of APC mutations 76 
result in the translation of a truncated protein and consequent deregulation of Wnt 77 
signaling (1, 2). Nevertheless, Wnt-independent roles of APC likely also contribute to its 78 
function as a tumor suppressor. This is exemplified by the rare detection of mutations in 79 
other Wnt signaling components, including b-catenin, in colorectal cancer (5). Although 80 
deletion of Apc in the intestinal epithelium in mice phenocopies homozygous truncation 81 
mutations, it leads to more rapid onset of tumors despite lower levels of Wnt activation 82 
(6). It thus emerges that loss of wild-type (WT) APC confers additional advantages to 83 
cells beyond b-catenin-mediated proliferation, but the extend of APC’s Wnt-independent 84 
functions is unclear.  85 
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A variety of proteins have been described to interact with APC in addition to b-86 
catenin destruction complex components (7). However, proteome-wide studies of APC-87 
binding proteins are limited to interactome and yeast-two-hybrid experiments with 88 
overexpressed, tagged and/or fragments of APC (8-11). Using tagged APC in 89 
interaction studies is problematic because the C-terminal PDZ-binding domain must 90 
remain free to interact with other proteins (12). Similarly, the N-terminal oligomerization 91 
domains rely on coiled-coil formation and may be compromised by N-terminal tags (13). 92 
To overcome these limitations, we used label-free affinity-enrichment mass 93 
spectrometry (AE-MS) to identify a more comprehensive set of interacting partners of 94 
endogenous, non-tagged APC. Furthermore, we applied an untargeted global approach 95 
using tandem mass tag (TMT)-based and label-free MS to identify proteins that are 96 
regulated by APC in their abundance. These two data sets provide a unique resource 97 
for the exploration of Wnt/b-catenin-dependent and independent functions of APC. In 98 
addition, we could identify potential targets of APC-containing destruction complexes by 99 
combining our data on APC-interacting and APC-regulated proteins (Figure 1A). While 100 
no direct evidence for the assembly of such complexes by APC exists, other 101 
components of the b-catenin destruction complex, such as GSK-3b and SCFb-TrCP, are 102 
known to have many targets (14, 15). We thus hypothesized that APC may directly 103 
regulate the abundance of other proteins in addition to b-catenin. 104 
 105 
Materials and Methods 106 
Cell Culture 107 
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Colo320, HeLa, and SW480 cells were obtained from the American Type Culture 108 
Collection. U2OS cells were obtained from CRUK. The HCT116-Hab92 cell line was a 109 
kind gift of Todd Waldman, HeLa SEC-C and U2OS SEC-C parental cell lines were a 110 
kind gift of Ron Hay, the U2OS Flp-Inä T-Rexä host cell line was a kind gift of Carol 111 
MacKintosh. Cells were grown at 37 °C and 5% CO2 in Dulbecco’s modified eagle 112 
medium (DMEM) with 10% fetal bovine serum, 50 U/mL penicillin/streptomycin, and 1% 113 
v/v non-essential amino acids (all Thermo Fisher Scientific). HeLa SEC-C, U2OS SEC-114 
C, U2OS Flp-In™ T-Rex™ and cell lines generated from these were grown as 115 
described above, with the addition of 100 µg/mL Hygromycin B and 15 µg/mL Blasticidin 116 
to the cell culture medium. Cells were culture for a maximum of 20 passages after 117 
thawing. Cells were tested for mycoplasma contamination every 6 months using 118 
MycoAlertTM (Lonza, Cat# LT-07-418). 119 
 120 
Generation of cell lines 121 
U2OS SEC-C MINK1 knockout cell lines  122 
Analysis of the N-terminal coding region of MINK1 (ensembl ENSG00000141503) 123 
predicted potential gRNAs with high target affinity, high efficiency and low off-target 124 
scores with binding sites in exon 1 and exon 2 using CRISPR Design. We used the best 125 
scoring gMINK1 target site in exon 1 (CGGACAGGTCGATGTCGTCC [AGG]) with a 126 
score of 95 and 12 predicted off-target sites in other genes. The gRNA sequence was 127 
cloned into pBabeD pU6 and sequence-verified. U2OS cells stably expressing Cas9 128 
(U2OS SEC-C) were co-transfected with 3 µg pBabeD pU6 gMINK1 using 129 
Lipofectamine 2000 according to the manufacturer’s instructions (Thermo Fisher 130 
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Scientific, Cat# 11668027). Cells were grown in DMEM supplemented with 10% FBS, 2 131 
mM L-glutamine, and 100 µg/mL Normocinä (InvivoGen, Cat# ant-nr-1). After 12 h, 132 
medium was replaced with fresh medium with 4 µg/mL Puromycin. After 48 h of 133 
selection, 2 µg/mL doxycycline was added to induce Cas9 expression. After 72 h, single 134 
cells were sorted with an Influx™ cell sorter (BD Biosciences) into 96-well plates 135 
containing DMEM with 20% FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL 136 
streptomycin, and 100 µg/mL Normocinä. MINK1 protein expression was screened by 137 
western blotting. Genomic DNA of MINK1 KO cells was amplified by PCR and 138 
sequenced to confirm the introduction of frameshift mutations. 139 
HeLa SEC-C mNeonGreen-MINK1  140 
The same pBabeD pU6 gMINK1 vector used for the generation of MINK1 knock-out 141 
cells was used for the fusion of mNeonGreen to the N-terminus of MINK1 in HeLa SEC-142 
C cells as described previously (16). A donor vector was designed to replace the ATG 143 
start codon of MINK1 with the start codon of an mNeonGreen cDNA cassette, flanked 144 
by ~500 bp homology arms. The donor vector was synthesized by GeneArt (Life 145 
Technologies). Expression of mNeon-MINK1 in selected and expanded single cell 146 
clones was validated by western blotting and microscopy. 147 
U2OS Flp-In T-Rex MINK1-GFP/GFP  148 
Stable cell lines with tetracycline/doxycyline-inducible expression of MINK1-GFP/GFP-149 
MINK1 and GFP, respectively, were generated using the Flp-InÔ T-RexÔ System 150 
according to the manufacturer’s instructions (Thermo Fisher Scientific) by transfecting 151 
U2OS Flp-InÔ T-RexÔ host cells with pcDNA5 FRT/TO C-GFP, pcDNA5 FRT/TO 152 
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MINK1-GFP, or pcDNA5 FRT/TO GFP-MINK1 respectively, and pOG44, a constitutive 153 
Flp recombinase expression plasmid. 154 
 155 
Generation of fly lines and mosaic follicular epithelia 156 
The YFP-fused, endogenously expressed allele msnCPTI003908 was recombined with the 157 
FRT[82B], apc1-, apc2- chromosome by meiotic recombination. msnCPTI003908, FRT[82B], 158 
apc1-, apc2- and Hs-flp ; Ubi-PHPLCδ1::RFP ; FRT[82B], Ubi-nls::RFP flies were crossed 159 
and apc1-, apc2- mutant clones in follicular epithelial cells in the resulting progeny were 160 
induced by a 2 hour, 37 °C heat-shock at a late (starting to pigment) pupal stage. 161 
 162 
Transfections 163 
For siRNA transfections cells were transfected one day after seeding with siGENOME 164 
APC siRNA #1-#3 (Dharmacon, Cat# D-003869-05/06/07), Hs_CTNNB1_5 FlexiTube 165 
siRNA (Qiagen, Cat# SI02662478), or siGENOME Non-Targeting siRNA #1 166 
(Dharmacon, Cat# D-001210-01-05) using INTERFERinÒ (Polyplus-Transfection, Cat# 167 
409-10) using 72 ng siRNA/T-25 flask. Colo320 cells were transfected twice on two 168 
consecutive days. For plasmid transfections cells were transfected one day after 169 
seeding with 4 µg myc-tagged b-catenin constructs (17)/10 cm dish using FugeneÒ 6 170 
Transfection Reagent (Promega, Cat#2691). 171 
 172 
Mice 173 
All mice were obtained from The Jackson Laboratory and bred and maintained in 174 
accordance with their recommendations under specific pathogen-free conditions in the 175 
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Biological Resource Unit at the University of Dundee. Compliant with the ARRIVE 176 
guidelines the project was approved by the University Ethical Review Committee and 177 
authorized by a project license under the UK Home Office Animals (Scientific 178 
Procedures) Act 1986. 179 
 180 
Protein and RNA harvest 181 
To harvest proteins, cells or cryo-pulverized mouse small intestinal tissue were lysed in 182 
50 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM EDTA, 5 mM EGTA, 40 mM b-183 
glycerophosphate, 0.5% NP-40, 1 mM sodium fluoride, 0.1 mM sodium orthovanadate, 184 
and 10 µg/mL of each leupeptin, pepstatin A, and chymostatin. Lysates were cleared by 185 
centrifugation and supernatants were collected for further processing. Total RNA was 186 
isolated using the NucleoSpinÒ RNA II Kit (Machery-Nagel, Cat# 740955.10).  187 
 188 
Immunoprecipitations 189 
For APC IPs 40 µl protein G-sepharose (Sigma-Aldrich, Cat# P-3296) was washed with 190 
protein lysis buffer and incubated for 12 h with 80 µg (for AE-MS)/20-40 µg (for WB) of 191 
ALI-12-28/C-APC 41.1 antibody (both CRUK) or control V5 tag antibody (kind gift of R. 192 
Hay) at 4 °C on a rotating wheel. Antibodies were crosslinked to sepharose using 193 
bis[sulfosuccinimidyl]suberate (Thermo Fisher Scientific, Cat# 21580). Antibody-194 
crosslinked sepharose was incubated with pooled cell lysates harvested from five 15 cm 195 
dishes (AE-MS and validation Co-IPs)/10 mg protein lysate (all other APC Co-IPs) for 196 
12 hours at 4 °C on a rotating wheel. 197 
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For GFP IPs 15 µl GFP-TrapÒ_A beads (Chromotek, Cat# gta-100) were washed twice 198 
with PBS and twice with protein lysis buffer. Lysates harvested from one 15 cm dish of 199 
U2OS Flp-In T-Rex MINK1-GFP/GFP-MINK1/GFP cells grown for two days in media 200 
containing 75 ng/mL Tetracycline was incubated with the beadsfor 4 hours at 4 °C on a 201 
rotating wheel. 202 
Beads were washed repeatedly with 20 mM Tris-HCl ph 7.5, 150 mM NaCl, 1 mM 203 
EDTA, 0.05% Triton X-100, and 5% glycerol (for APC IPs) or protein lysis buffer (for 204 
GFP-IPs). Proteins were eluted by boiling with 1.3x NuPAGEÔ LDS sample buffer 205 
(Thermo Fisher Scientific, Cat# NP0008). 206 
 207 
SDS-PAGE and Western Blotting 208 
Protein samples (50 µg (cell lysates)/100 µg (tissue lysates) were separated on pre-cast 209 
NuPAGEÔ 4-12% gradient Bis-Tris polyacrylamide protein gels (Thermo Fisher 210 
Scientific, Cat# NP0322/NP0321), transferred to nitrocellulose membrane, and blotted 211 
with primary antibodies: anti-ABI2 (Cat# 302-499A, RRID: AB_1966095), anti-GIT1 212 
(Cat# 302-101A, RRID: AB_1604200), anti-GIT2 (Cat# 302-103, RRID: AB_1604269), 213 
anti-RNF20 (Cat# 300-714A, RRID: AB_533428), anti-hPrp3p (Cat# 302-073A, RRID: 214 
AB_1604202), anti-MINK1 (Cat# A302-192A, RRID: AB_1659822), anti-PAK1 (Cat# 215 
301-259A, RRID: AB_890620), anti-PDZ-GEF2 (Cat# 301-967A, RRID: AB_1548003), 216 
anti-RNF25 (Cat# 303-844A, RRID: AB_2620195; all Bethyl Laboratories); anti-Aurora 217 
B (Cat# ab2254, RRID: AB_302923), anti-CASK (Cat# ab99039, RRID: AB_10696957), 218 
anti-LATS1 (Cat# ab70562, RRID: AB_2133360; all Abcam); anti-GAPDH (Millipore, 219 
Cat# MAB374, RRID: AB_2107445); anti-GFP (Clontech Laboratories, Cat# 632381; 220 
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RRID: AB_2313808); anti-LSM7 (Cat# 18941-1-AP, RRID: AB_10596483), anti-TBP 221 
(Cat#66166-1-Ig, both Proteintech) anti-b-catenin (BD Transduction Laboratories, Cat# 222 
610154, RRID: AB_397555); sheep polyclonal anti-GFP (MRC PPU Dundee, S268B); 223 
mouse monoclonal anti-APC N-terminus (CRUK, ALI-12-28); rabbit polyclonal anti-APC 224 
N-terminus (18); anti-b-catenin (19). Anti-mouse/rabbit Alexa Fluor Plus 800/680-225 
conjugated secondary antibodies (Thermo Fisher Scientific, Cat# A32735, RRID: 226 
AB_2633284/Cat# A32730, RRID: AB_2633279/Cat# A32734; RRID: 227 
AB_2633283/Cat# A32729, RRID: AB_2633278) were detected and quantified with the 228 
Li-Cor Odyssey imaging system and Image Studio Software. 229 
 230 
Immunofluorescence and live imaging 231 
Cells 232 
For immunofluorescence, cells grown on collagen-coated No. 1.5 cover glass were fixed 233 
for 10 min with -20 °C methanol, permeabilized using 1% NP40 in PBS for 10 min, and 234 
incubated with IF blocking buffer (5% normal goat serum, 2% w/v BSA, 0.1% Triton X-235 
100 in 1x PBS) for 30 min at RT. Cells were washed with 0.2% w/v BSA in 1x PBS, in 236 
between steps. Anti-MINK1 antibody (Thermo Fisher Scientific, Cat #PA5-28901, RRID: 237 
AB_2546377) was diluted 1:250 in blocking buffer without serum and incubated 238 
overnight at 4 °C. After repeated washing, cells were incubated for one hour with 239 
20 µg/mL Hoechst 33342 (Invitrogen, Cat# H3570) and Alexa FluorÒ 594 anti-rabbit 240 
antibody (Thermo Fisher Scientific, Cat #PA5-28901; RRID: AB_2546377) diluted 241 
1:500. Cover slips were mounted onto microscopy slides using 90% glycerol with 0.5% 242 
N-propyl gallate. For live imaging, cells were grown on 35 mm glass bottom dishes 243 
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(ibidi, Cat# 81418-200) in DMEM without phenol red. Images were acquired with an 244 
inverted Nikon Eclipse Ti-E fluorescence microscope equipped with a Hamamatsu 245 
ORCA-R2 digital CCD camera and a Prior Scientific Lumen 200PRO light source, using 246 
a Plan Apo 60x NA 1.4 objective lens. Images were acquired with the MetaMorph 247 
software (version 7.8.12.0) and without camera binning. 395/25; 480/40; and 545/30 248 
excitation and 460/50; 535/50; and 620/60 emission filters were used for Hoechst, 249 
mNeonGreen, and Alexa594. Image brightness and contrast was adjusted equally for 250 
each image using Fiji software (20). 251 
Drosophila egg chambers 252 
Msn::YFP-expressing, mosaic apc1-, apc2- mutant female flies were dissected 24 hours 253 
after hatching. Ovaries dissected in glucose- (1 g/L) and insulin- (0.2 g/L) supplemented 254 
Schneider’s medium (Lonza, Cat# Iz04-351q) in a 35 mm glass bottom dish into 255 
individual ovarioles. Imaging was performed on a SP8 confocal microscope (LEICA) 256 
equipped with a 63x NA 1.2 water immersion objective within the hour following 257 
dissection. The Nls::RFP marker was used to discriminate apc1-, apc2- mutant 258 
cells, apc1+, apc2+ control cells and apc1-, apc2- /apc1+, apc2+ heterozygous control 259 
cells. Msn::YFP levels were measured at the interface between cells of the same 260 
genotype and, for each egg chamber, normalized to the median value measured at the 261 
interfaces between heterozygous control cells. 262 
 263 
Cell adhesion assay 264 
96-well plates coated with 10 µg/cm2 collagen (Sigma-Aldrich, Cat# 8919) were washed 265 
with PBS and incubated for one hour with DMEM + 0.5% bovine serum albumin (BSA) 266 
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at 37 °C. Cells were detached with 10 mM EDTA in PBS for 10 min at 37 °C, washed 267 
twice with DMEM, counted using a CellometerÒ Auto T4 bright field cell counter 268 
(Nexcelom Bioscience), and diluted to a density of 1´105 cells/mL in DMEM + 0.1% 269 
BSA. 10,000 cells were added per well and incubated for 1 h at 37 °C. Loosely attached 270 
cells were removed by vigorous shaking of the plate for 10 s, and washing with DMEM + 271 
0.1% BSA. Adherent cells were fixed with 4% paraformaldehyde for 10 min, washed, 272 
and stained for 10 min with 5 mg/mL crystal violet in 2% ethanol. Plates were washed 273 
once with water and then dried overnight. Crystal violet stain was solubilized with 200 µl 274 
2% SDS/well for 30 min and diluted 1:4 with water. Absorption was measured at 550 nm 275 
using a Synergy H1 Hybrid multi-mode microplate reader (BioTek). 276 
 277 
MTT cell proliferation assay 278 
Cells were seeded one day after transfection in 96 cells plates with 1´105 cells/well. 279 
Viable cells was measured using the TACSÒ MTT Proliferation Assay Kit (Trevigen, 280 
Cat# 4890-25-01 and Cat# 4890-25-02). 281 
 282 
Real Time-quantitative PCR (RT-qPCR) 283 
cDNA was synthesized using the qScriptä cDNA Synthesis Kit (Quanta Biosciences, 284 
Cat# 95047). RT-qPCR reactions were performed in triplicate using PerfeCTa SYBR® 285 
Green FastMix (Quanta Biosciences, Cat# 95072) and a CFX ConnectÔ Real-Time 286 
PCR Detection System (Bio-Rad). CT values obtained for target genes were normalized 287 
to ACTB and relative mRNA expression was calculated using the Pfaffl method (21). 288 
Primer sequences: ACTB forward/reverse – 289 
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CTGGGAGTGGGTGGAGGC/TCAACTGGTCTCAAGTCAGTG, AXIN2 forward/reverse: 290 
TGGCTATGTCTTTGCACCAG/TGTTTCTTACTGCCCACACG, CTNNB1 291 
forward/reverse: ATGGCTTGGAATGAGACTGC/TTCCATCATGGGGTCCATAC, 292 
MINK1 forward/reverse: TCAACCTGCTCATCACCATC/TCCACTTCTGGGTCATTGTG. 293 
 294 
Protein analysis by mass spectrometry 295 
For label-free MS analysis Co-IP and complete lysate samples were separated by SDS-296 
PAGE and proteins were visualized by Coomassie Blue staining. Gel lanes were 297 
subdivided into three parts – gel regions containing co-eluted antibody chains in Co-IP 298 
samples were pooled. In-gel tryptic digestion was performed as described previously 299 
(22). Peptides solubilized in 1% FA were analyzed by LC-MS/MS on a Q Exactive mass 300 
spectrometer (Thermo Scientific) coupled to an EASY-nLC 1000 liquid chromatography 301 
system via an EASY-Spray ion source (Thermo Scientific) with a 75 µm ´ 500 mm 302 
EASY-Spray column (Thermo Scientific) heated to 40 °C. An elution gradient duration of 303 
240 min was used, fractionating mostly over the 3-40% acetonitrile range. Data were 304 
acquired in the data-dependent acquisition mode. Full scan spectra (300-1800 Th) were 305 
acquired with resolution of 70,000 at 400 Th (after accumulation to a target value of 306 
1,000,000 with maximum injection time of 20 ms). The ten most intense ions were 307 
fragmented by higher-energy collisional dissociation (HCD) and measured with 308 
resolution 17,500 at 200 m/z and a target value of 500,000, with a maximum injection 309 
time of 60 ms. Intensity threshold was 2.1e4. Unassigned, +1 and >8+ charge peptides 310 
were excluded, and peptide matching was set to “preferred”. A 40 second dynamic 311 
exclusion list was applied. 312 
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For TMT-label MS analysis samples were processed as previously described (23). 313 
Two µg of each sample were analyzed on an Orbitrap Fusion Lumos mass 314 
spectrometer coupled to a Proxeon EASY-nLC 1200 liquid chromatography pump (both 315 
Thermo Fisher Scientific) and a 100 µm ´ 35 cm microcapillary column packed with 316 
Accucore C18 resin (2.6 µm, 150 Å; Thermo Fisher). Peptides were fractionated over a 317 
150 min gradient of 3 – 25% acetronitrile in 0.125% formic acid. An MS3-based TMT 318 
method was used, as described previously (24). 319 
 320 
Raw MS data analysis 321 
Raw MS data files were processed using MaxQuant (25, version 1.5.8.3) using default 322 
settings. MS/MS spectra were searched against the UniProt human proteome sequence 323 
database. The MaxLFQ algorithm was implemented, applying a minimum ratio count of 324 
2. For label-free samples the ‘match between runs’ option with default settings was 325 
enabled. TMT-labelled samples were quantified by reporter ion MS3 – TMT10plex (Lys 326 
& N-terminal 126C-130N), with a reporter mass tolerance of 0.003 Da. One percent 327 
FDR filtering was applied at protein and peptide levels. 328 
 329 
MS data processing 330 
Further MS data analysis was performed using Perseus (26, version 1.5.8.5). ‘Reverse’ 331 
proteins, proteins ‘only identified by site’, and all non-human contaminants and human 332 
contaminants, except cytoskeletal components, were filtered out. Data were log2 333 
transformed. The filtered APC AE-MS data set contained 5,571 identified proteins, of 334 
which 5,521 were measured. From these only proteins measured in all four replicates of 335 
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at least one IP with N-APC, C-APC or control antibody were carried forward (4,016 336 
proteins). Missing values were imputed from a normal distribution using standard 337 
settings (width: 0.3 ´ standard deviation of measured values, down shift: 1.8 in units of 338 
standard deviation of measured values).  339 
The filtered label-free proteome data set contained 5,982 identified proteins, of which 340 
4,927 were measured in at least three replicates of at least one condition and only these 341 
were used for further analysis. Missing values were imputed from a normal distribution. 342 
The filtered TMT proteome data set contained 6,949 identified proteins, of which 6,923 343 
were measured in all analyzed samples. Only these proteins were used for further 344 
analysis. 345 
Enrichment analysis of category terms within the group of potential APC interactors 346 
identified by AE-MS (171 proteins) relative to all proteins measured in this experiment 347 
(4,016 proteins) was calculated by Fisher Exact Test using default settings with a 348 
Benjamini-Hochberg FDR <0.02 used for truncation. 349 
 350 
Network generation 351 
The APC interaction network was generated in Cytoscape (27, version 3.5.0) using 352 
information on APC interactors listed in the IntAct Molecular Interaction Database 353 
and/or BioGRID interaction repository. Low-confidence links (IntAct MI score <0.6), 354 
individual nodes detached from the network, and indirect APC interactors with less than 355 
two connections were deleted. The network layout was generated using the Weak 356 
Clustering algorithm and the IntAct MI score for edge weighting within the Cytoscape 357 
Allegro Layout App. 358 
 
 17 
 359 
 360 
Results 361 
Identification of APC-interacting proteins by affinity enrichment-mass spectrometry (AE-362 
MS) 363 
For our initial discovery experiments, we used HeLa cells, which express relatively high 364 
amounts of wild-type APC that can be efficiently depleted by siRNA. This allowed us to 365 
measure protein binding to, and regulation by, APC in the same cell line. APC-366 
containing protein complexes were co-immunoprecipitated using two APC-specific 367 
monoclonal antibodies that recognize N- and C-terminal domains, respectively. An 368 
isotype-matched antibody against the viral V5 peptide was used as control. Co-369 
immunoprecipitation (Co-IP) with each antibody was performed in quadruplicate. 370 
Samples were analyzed by label-free tandem mass spectrometry (LC-MS/MS). We only 371 
considered the 4,016 proteins that were detected in all four replicates of Co-IP’s with 372 
either antibody for further analysis. Pearson correlation coefficients >0.9 for label-free 373 
quantification (LFQ) intensities measured across replicates and a clear separation of N-374 
APC, C-APC and control Co-IPs by principal component analysis (PCA) indicated good 375 
experimental reproducibility (Supplementary Figures S1A and B). Significant enrichment 376 
of proteins in APC-specific versus control Co-IPs was determined by considering both 377 
permutation-based FDR (<0.01) and LFQ intensity fold-change (Supplementary Figure 378 
S1C). 379 
In total, 171 proteins were significantly enriched in APC-specific Co-IPs (Figure 380 
1B and Supplementary Table S1). These proteins will be referred to hereafter as the 381 
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‘APC interactome’. Eighty and 71 proteins were exclusively enriched in either C-APC or 382 
N-APC Co-IPs, respectively. Antibody binding to APC is likely affected by protein 383 
interactions at domains close to or overlapping with the antibody epitopes. This could 384 
explain co-immunoprecipitation of distinct interactors with different APC-specific 385 
antibodies. Consistently, C-APC and N-APC antibodies immunoprecipitated 386 
overlapping, but distinct, pools of APC that may contain different subsets of binding 387 
partners (Supplementary Figure S1D). Twenty proteins, including APC itself, were 388 
significantly enriched in both APC Co-IPs and only half of these were previously 389 
described APC interactors (28,29; Supplementary Table S1). 390 
To rule out a HeLa cell-specific enrichment of proteins in APC Co-IPs, we 391 
validated our AE-MS results in the human colon carcinoma cell line HCT116-Hab92, 392 
which are homozygous for wild-type APC and hemizygous for wild-type b-catenin (30). 393 
Thirteen of the novel APC-interacting proteins were selected to cover the range of 394 
biological functions represented in the data set and based on antibody availability. 395 
Consistent with results obtained by AE-MS, 12/13 proteins were enriched in APC Co-396 
IPs in both cell lines (Supplementary Figure S2). 397 
 398 
The APC interactome is enriched for epithelial-specific GO cellular component terms 399 
To identify underlying functional patterns, we analyzed the enrichment of gene ontology 400 
(GO), protein family (Pfam), and Kyoto encyclopedia of genes and genomes (KEGG) 401 
terms in the APC interactome. Thirty-one terms were significantly over-represented 402 
(Benjamini-Hochberg FDR <0.02); the majority can be broadly categorized into three 403 
cellular processes: (actin) cytoskeleton organization, cell-cell contact establishment, and 404 
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RNA processing (Figure 1C, Supplementary Table S1). APC-interacting proteins 405 
associated with cytoskeletal organization included known and newly identified 406 
interactors, including several SCAR complex components. The enrichment of terms 407 
linked to RNA processing is consistent with APC’s role as an RNA-binding protein (31). 408 
Strikingly, many of the enriched terms are associated with cell-cell contacts and 409 
constitute components characteristic of epithelial cells, e.g. “lateral plasma membrane”, 410 
“tight junctions”, and “cell-cell adherens junction”. 411 
 412 
Generation of an integrated APC interaction network 413 
To understand the relationship between interaction partners, we tested how our 414 
interactome integrated into a network of previously identified APC-binding proteins. Our 415 
interactome data set overlaid well with, and added substantially to, the network of 416 
known APC-binding proteins (Figure 2). The integrated network revealed many direct 417 
and indirect high-confidence links between newly identified and known APC interactors 418 
suggesting potential APC-interacting protein complexes. In addition to the ‘b-catenin 419 
destruction complex’ cluster, several sub-networks emerged from this analysis. Two of 420 
these included proteins associated with ‘LSM protein family’ and ‘SCAR complex’, 421 
respectively, and both categories were enriched in our APC interactome data set 422 
(Figure 1C). 423 
To validate our network analysis, we generated a control network using 171 424 
proteins randomly selected from the APC AE-MS data set. Compared to the random 425 
selection, our interactome exhibited superior integration into the network of known APC-426 
binding partners (Supplementary Figure S3). 427 
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 428 
APC affects the abundance of many proteins independently of β-catenin 429 
Because our APC interactome included many binding partners that appeared unrelated 430 
to Wnt signaling components, we aimed to determine whether APC is involved in the 431 
regulation of proteins other than β-catenin, and independently of β-catenin-mediated 432 
cellular effects. To this end, we depleted APC alone or together with β-catenin from 433 
HeLa cells using siRNA and measured changes in protein abundance by mass 434 
spectrometry (MS). Cells were harvested 72 hours after transfection and efficient 435 
knockdown was confirmed by western blotting (WB, Supplementary Figure S4A). 436 
Simultaneous knockdown of APC and β-catenin abrogated β-catenin target gene 437 
activation, as verified by the inhibition of AXIN2 mRNA transcription (Supplementary 438 
Figure S4D). For each siRNA combination, we analyzed four and two experimental 439 
replicates by label-free and TMT MS, respectively. Downstream analysis was applied to 440 
6,923 proteins measured in all eight samples by TMT MS and 4,927 proteins measured 441 
in at least three replicates of at least one condition by label-free MS. Reproducibility 442 
between replicates was very good, as indicated by Pearson correlation coefficients 443 
>0.97 and a clear separation of distinct siRNA treatments by PCA (Supplementary 444 
Figure S4B and C).  445 
To identify proteins that changed in abundance in response to APC depletion, but 446 
independently of β-catenin, we compared TMT/LFQ intensities across conditions of all 447 
measured proteins to an “ideal” intensity profile of a hypothetical β-catenin-independent 448 
APC target. A negative APC target was defined as a protein that increased in 449 
abundance in response to APC loss, independently of whether APC was depleted alone 450 
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or together with β-catenin, but which protein levels did not change in β-catenin siRNA 451 
compared to control siRNA-treated cells (the intensity profile of an “ideal” negative APC 452 
target is indicated in red in Figure 3A top right). Conversely, a positive APC target was 453 
defined as a protein that decreased in abundance in response to APC depletion, 454 
independent of β-catenin status. The 200 proteins with profiles most similar to the ideal 455 
negative and positive APC target were selected based on Pearson correlation. 456 
Significant β-catenin-independent APC targets were determined by applying an 457 
additional cut-off of >1.5 fold-change in APC and APC+β-catenin siRNA-treated 458 
samples relative to control with a q-value <0.05 (TMT)/0.1 (LFQ). By TMT MS we 459 
identified 53 and 85 proteins that significantly increased and decreased, respectively, in 460 
response to APC depletion in a β-catenin-independent manner; by LFQ MS 11 proteins 461 
increased and 11 decreased (Figure 3A/B and E/G). Four negatively and seven 462 
positively regulated proteins were common to both data sets. This group of proteins was 463 
not enriched in distinct GO terms (data not shown), but spanned a range of cellular 464 
functions including apoptosis, ion transport, actin organization, and proliferation.  465 
To compare APC’s β-catenin-dependent and -independent effects on protein 466 
expression, we also identified proteins that changed in abundance in response to APC 467 
depletion in a β-catenin-dependent manner. The number of these proteins was similar 468 
to those regulated independently of β-catenin: 64 and 37 were negatively regulated, 86 469 
and 103 were positively regulated when detected by TMT and LFQ MS respectively 470 
(Figure 3C/D and F/H, Supplementary Table S2). 471 
 472 
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Some β-catenin-independent APC targets are also deregulated in human cancer 473 
To determine if any of the identified β-catenin-independent APC targets are implicated 474 
in colorectal cancer, we compared our results with a dataset describing proteomic 475 
changes in human colorectal adenoma and adenocarcinoma compared to healthy 476 
mucosa (32). Nineteen proteins present in our APC target list were also found to be 477 
dysregulated – in the same direction – in human adenomas and/or carcinomas (Table 478 
1). These results highlight that mis-expression of some proteins in colorectal cancer 479 
could be a direct consequence of loss of WT APC rather than deregulated Wnt 480 
signaling. 481 
 482 
MINK1 interacts with full length and truncated APC 483 
From the group of b-catenin-independent APC targets identified by total proteomics 484 
analysis, six were also found to interact with APC. Amongst these, MINK1 stood out as 485 
a potentially druggable serine/threonine kinase. We validated the interaction between 486 
MINK1 and full-length APC by Co-IP and WB in two cell lines (Figure 4A). In agreement 487 
with results obtained by MS, MINK1 was only enriched in Co-IPs with the N-APC 488 
antibody (Supplementary Figure S5A). To rule out N-APC antibody cross-reactivity, we 489 
repeated the experiment with lysate from APC-depleted cells. Confirming its specific 490 
enrichment in APC protein complexes, the amount of co-immunoprecipitated MINK1 491 
correlated with the levels of APC present in IP lysates (Supplementary Figure S5B). 492 
Conversely, APC was also enriched in Co-IPs of over-expressed GFP-tagged MINK1 493 
compared to GFP alone (Supplementary Figure S5C). We next tested whether MINK1 494 
could also interact with truncated APC expressed in colorectal cancer cells. MINK1 co-495 
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immunoprecipitated with APC fragments in both SW480 and Colo320 cells (Figure 4B). 496 
The ~90 kDa N-terminal APC fragment expressed in Colo320 cells retains the armadillo 497 
and oligomerization domain, but lacks all b-catenin and Axin binding sites and other C-498 
terminal domains. The ~220 kDa APC fragment expressed in SW480 cells includes the 499 
four most N-terminal b-catenin binding sites. These data suggest that the interaction 500 
between the two proteins is mediated by domains in the N-terminal third of APC. 501 
 502 
MINK1 is negatively regulated by APC independently of b-catenin 503 
Consistent with our proteomics data, MINK1 levels measured by WB significantly 504 
increased after 72 h of APC depletion in HeLa and U2OS cells and this accumulation 505 
was independent of changes in b-catenin (Figure 4C and Supplementary Figure S5D 506 
and S6A). Similar to results obtained with the siRNA pool, transfection with either of the 507 
individual APC siRNAs efficiently decreased APC levels and produced a concomitant 508 
increase in MINK1 protein (Supplementary Figure S5E). We validated the effect of APC 509 
loss on MINK1 levels in vivo by measuring protein expression in intestinal tissue from 510 
Apc mutant and wild-type mice. Mink1 protein was increased by 2.3-fold (±0.4 SD) in 511 
ApcMin/+ versus control animals (Figure 5A and 5B). In addition, we addressed whether 512 
this regulatory relationship is conserved across species. We generated mosaic follicular 513 
epithelia in Drosophila melanogaster egg chambers carrying clones of 514 
double APC1, APC2 mutant cells (marked by loss of NLS::RFP expression). Measuring 515 
levels of a YFP-fused Misshapen protein – the closest orthologue in Drosophila - 516 
(Msn::YFP) using live microscopy revealed that Msn::YFP levels were significantly 517 
higher in cells that did not express APC1 and APC2 (Figure 5C-F). 518 
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 519 
Parallels between the regulation of MINK1 and b-catenin protein abundance 520 
We hypothesized that APC regulates the abundance of MINK1 – similarly to b-catenin – 521 
post-transcriptionally. Transfection with APC siRNA resulted in a significant up-522 
regulation of AXIN2 mRNA, and this increase was efficiently inhibited when APC and b-523 
catenin were depleted simultaneously. In contrast, MINK1 mRNA increased moderately 524 
but changes in MINK1 mRNA did not correlate with changes in MINK1 protein 525 
abundance (Figure 6A and 4C).  526 
We further tested whether the degradation of MINK1, similarly to b-catenin, was 527 
dependent on the action of an E3 ubiquitin ligase. Treatment with the NEDD8-activating 528 
enzyme selective inhibitor MLN4924, which inhibits cullin-RING ubiquitin ligase activity 529 
(33), reproducibly induced a two-fold increase in MINK1 after 24 h (Figure 6B and 530 
Supplementary Figure S6B).  531 
 532 
MINK1 localizes to cell-cell junctions and enhances cell adhesion and proliferation 533 
To address how elevated MINK1 could contribute to cellular processes affected by APC 534 
mutations, we determined its sub-cellular localization. In agreement with a previous 535 
study (34), immunofluorescence staining showed an enrichment of signal in the 536 
perinuclear region (Supplementary Figure S6C). Nevertheless, a similar signal was 537 
present in MINK1 knockout cells, suggesting cross-reactivity of this MINK1 antibody 538 
with Golgi components. Indeed, the MINK1 antibody used for immunofluorescence 539 
recognized additional proteins by WB (Supplementary Figure S6D, the MINK1 antibody 540 
we used for WB was unsuitable for immunofluorescence).  541 
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To overcome this problem, we generated cells expressing endogenously 542 
mNeonGreen-tagged MINK1, enabling us to study its localization live in un-fixed cells 543 
(Supplementary Figure S6D). Although fluorescence intensity was low, mNeonGreen 544 
signal was clearly enriched at tips of protrusions (*) and at lateral plasma membranes 545 
(arrow heads) in areas of cell-cell contact (Figure 6C). No signal enrichment was 546 
detected in ‘free’ regions of the plasma membrane without adjoining cells. Consistent 547 
with a role for MINK1 in adhesion, overexpression of MINK1 resulted in a significant 548 
increase in cell attachment to collagen (Figure 6D and Supplementary Figure S6E). 549 
Furthermore, proliferation of colorectal cancer cells in which regulation of MINK1 by 550 
APC was lost (Supplementary Figure S6F), was significantly reduced when MINK1 was 551 
depleted using siRNA (Figure 6E). 552 
 553 
 554 
Discussion 555 
We aimed to elucidate – on a global scale – the diverse molecular roles of APC, with an 556 
emphasis on its functions beyond the b-catenin destruction complex. To this end, we 557 
applied an untargeted approach using label-free and TMT-based MS to assemble an 558 
APC interactome and, furthermore, to identify the b-catenin-independent APC-regulated 559 
proteome. These data sets provide a useful resource for the identification of proteins 560 
that participate in and coordinate Wnt-independent functions of APC. 561 
 In contrast to previous interaction studies, we used endogenous, full-length, and 562 
non-tagged APC in our AE-MS experiment. The identification of additional PDZ domain-563 
containing APC interaction partners highlighted the benefit of this approach. 564 
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Strikingly, the APC interactome was highly enriched for proteins that are part of cellular 565 
components characteristic for epithelial cells, as well as members of the membrane 566 
associated “guanylate kinase” (MAGUK) protein family, and PDZ-domain containing 567 
proteins (Figure 1C). MAGUK proteins are implicated in the establishment of epithelial 568 
cell polarity (35). Furthermore, the function of APC in epithelia is – at least partly – 569 
mediated by PDZ domain-containing proteins (36). In addition, STRIPAK complex 570 
components formed a highly connected cluster within the APC interaction network 571 
(Figure 2). APC and the STRIPAK component Striatin localize interdependently to cell-572 
cell junctions in epithelial cells and depletion of Striatin and APC affects tight junction 573 
organization (8). It is conceivable that binding to APC regulates the sub-cellular 574 
localization, activity, and/or expression of these epithelial-characteristic proteins, in turn 575 
controlling cellular adhesion and establishment of epithelial polarity. Investigating these 576 
interactions further will provide useful insights into the mechanisms that regulate APC 577 
function in different tissues and further improve our understanding of the phenotypes 578 
associated with APC loss. Such studies could reveal why APC germ line mutations in 579 
FAP patients result in cancerous lesions of the gut epithelium, while other organs often 580 
remain unaffected. 581 
Measuring proteome-wide effects of APC loss revealed a set of b-catenin-582 
independent APC targets, supporting a role of APC in the regulation of protein 583 
abundance beyond the b-catenin destruction complex (Figure 3). Similar to the effect on 584 
b-catenin, depletion of APC resulted in the accumulation of some proteins, while the 585 
levels of others were negatively affected, suggesting that APC can also inhibit 586 
degradation of some of its targets. Strikingly, the number of proteins regulated by APC 587 
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independent and dependent of b-catenin was very similar. It is important to 588 
acknowledge that untargeted MS is biased towards detection of more abundant 589 
proteins. Consistently, many established, but low-abundant, β-catenin targets, such as 590 
Myc and Axin2, were not detected and are thus absent from our analysis. However, this 591 
bias operates in both sets of targets equally. Changes in the abundance of individual 592 
APC targets could result from alterations in PTMs and/or protein stability – as is the 593 
case for b-catenin. This is supported by previous findings in Drosophila, where loss of 594 
APC2 causes proteome-wide and b-catenin-independent changes in post-translational 595 
modifications that also affect protein stability of some proteins (37). In addition, effects 596 
on transcription may also contribute to the differences in protein abundance observed in 597 
our study.  598 
Since we have used HeLa cells (which we chose for technical reasons, see 599 
Results section) in our discovery MS experiments, we were unable to identify potential 600 
APC interacting proteins and/or targets which expression is e.g. restricted to intestinal 601 
epithelial cells. This limitation will need to be addressed in future studies - ideally using 602 
human/mouse intestinal tissue expressing wild-type and mutant APC. 603 
At present, it remains unclear how changes in these APC targets contribute to 604 
the functional consequences of APC loss observed in vivo. As a first step towards 605 
addressing this question, we compared our data set with data describing proteome-wide 606 
changes in colon adenomas and carcinomas (32). Several of the b-catenin-independent 607 
APC targets we identified were also found to be dysregulated in colorectal adenomas 608 
and/or tumors (Table 1). Among these, NDRG1, which was downregulated in APC-609 
depleted cells in our study and also in cancerous tissue, might be of particular interest. 610 
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NDRG1 has been established as a tumor suppressor in colorectal cancer cells based 611 
on its negative effects on metastasis and apoptosis (38).  612 
Collectively, our results suggest that part of the protein expression changes 613 
observed in colorectal cancer are independent of increased Wnt target gene 614 
expression. Investigating the functional impact of these changes will further help to 615 
elucidate how APC loss contributes to cancer development beyond de-regulated b-616 
catenin. Accounting for these effects will be especially important when considering 617 
cancer therapy, as they reveal that consequences of mutant APC protein cannot be fully 618 
rectified by restoring normal Wnt signaling. 619 
 620 
Little is known about the functions of MINK1 or the regulation of its activity and/or its 621 
abundance. Existing data implicate MINK1 in cell adhesion, cell migration and planar 622 
cell polarity (PCP; 34,39,40) - processes crucial for epithelial biology. Furthermore, 623 
MINK1 kinase activity is required for completion of cytokinesis (41). Importantly, these 624 
processes are also deregulated in APC mutant tissues (42-44). Moreover, TRAF2 and 625 
NCK-interacting protein kinase (TNIK), which shares high sequence homology with 626 
MINK1, is emerging as a promising target for colorectal cancer therapy, as it regulates 627 
the activity of the TCF-4/b-catenin transcription complex (45). 628 
 Collectively, our results indicate that MINK1 is regulated by APC in a manner 629 
similar to b-catenin (Figure 4 and 6). Importantly, increased Mink1/Msn levels after loss 630 
of wild-type Apc/APC1,2 were also observed in vivo, in mouse intestinal tissue and 631 
follicular cells in Drosophila (Figure 5). Consistent with its localization to cell-cell 632 
junctions, over-expression of MINK1-GFP resulted in increased cell adhesion (Figure 633 
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6C, D). This is in contrast to a previous study, in which cells overexpressing full-length 634 
MINK1 did not grow in clusters but in isolation, suggesting decreased adhesion between 635 
cells (34). However, in this case, the effects were not quantified and additional studies 636 
of MINK1 overexpression on cell-cell adhesion do not exist. It is conceivable, that 637 
enhanced cell adhesion due to elevated MINK1 expression contributes to the reduced 638 
cell migration observed in APC mutant tissue (43, 46). Moreover, directionality of cell 639 
migration could be disturbed when MINK1 expression is deregulated in response to 640 
APC loss. Evidence for a role of mammalian MINK1 in PCP is limited (39); however, a 641 
role for its Drosophila homologue Msn in epithelial PCP has been firmly established 642 
(47). In flies, both Apc and Msn act downstream of Dishevelled, which was described as 643 
a ‘branchpoint’ between the canonical Wnt and the non-canonical PCP pathway (48). 644 
Our results indicate that regulation of Msn by APC is conserved in flies (Figure 5C-F), 645 
suggesting an additional level of crosstalk between these signaling pathways. 646 
Furthermore, knockdown of MINK1 in colorectal cancer cells resulted in a significant 647 
reduction in proliferation, comparable to the effect seen with b-catenin depletion (Figure 648 
6E). Future experiments will focus on elucidating the molecular mechanisms of MINK1 649 
regulation by APC and the identification of downstream effectors mediating the effects 650 
of MINK1 overexpression on cell adhesion. 651 
 652 
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Tables 822 
Table 1. Overlap between β-catenin-independent APC targets identified in this study and proteins mis-expressed in 823 
colorectal polyps and/or tumors (31). 824 
Protein name 
(identified by TMT and/or 
LFQ) 
Log2 fold change q value  Log2 fold change 
(Wiśniewski et al. 
2015 – ref 31) 
 APC 
siRNA 
/control 
β-catenin 
siRNA 
/control 
APC+ 
β-catenin 
siRNA 
/control 
APC 
siRNA 
/control 
β-catenin 
siRNA 
/control 
APC+ 
β-catenin 
siRNA 
/control 
 polyps 
/normal 
tumor 
/normal 
60S ribosomal export protein 
NMD3 (TMT/LFQ) 
2.79/4.54 0.89/2.62 2.02/3.77 <0.001 0.019/0.027 <0.001  0.67 1.46 
Peptidyl-prolyl cis-trans 
isomerase FKBP10 (TMT/LFQ) 
1.16/1.13 0.49/0.74 1.00/1.03 0.004/0.04 0.062/0.238 0.003/0.087  0.06 1.95 
Melanoma-associated antigen 
D2 (LFQ) 
1.52  1.04  1.29  0.021  0.09 0.047  1.07 2.21 
Nucleolar protein 58 (LFQ) 0.93  0.48  1.03  0.059 0.238 0.098  1.5 1.25 
6-pyruvoyl tetrahydrobiopterin 
synthase (TMT) 
1.97 0.51 1.29 <0.001 0.057 0.007  1.67 0.66 
Glycerophosphocholine 
phosphodiesterase GPCPD1 
(TMT) 
1.46 0.41 0.94 0.012 0.083 0.007  1.34 1.19 
Hermansky-Pudlak syndrome 5 
protein (TMT) 
0.74 0.28 0.67 0.002 0.154 0.011  1.14 0.68 
Ubiquitin carboxyl-terminal 
hydrolase 8 (TMT) 
1.04 0.44 0.73 0.003 0.069 0.006  0.58 -0.23 
Zinc finger protein 622 (TMT) 1.26 -0.19 0.74 0.006 0.283 0.006  0.44 0.80 
          
Ras-related protein Rab-14 
(TMT/LFQ) 
-1.77/ 
-1.48 
-0.08/ 
-0.24 
-1.39/ 
-1.01 
<0.001/ 
0.025 
0.568/ 
0.384 
<0.001/ 
0.086 
 -0.55 -0.27 
Aldehyde dehydrogenase 
family 1 member A3 (LFQ) 
-1.98 -0.58 -1.45 0.009 0.192 0.041  -1.14 -0.69 
cAMP-dependent protein 
kinase type I-alpha regulatory 
subunit (TMT) 
-0.71 0.09 -0.61 0.002 0.518 0.011  -0.77 -1.33 
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Dolichol-phosphate 
mannosyltransferase subunit 1 
(TMT) 
-1.09 -0.07 -0.93 0.004 0.617 0.008  -0.97 0.07 
EH domain-containing protein 1 
(TMT) 
-0.60 -0.20 -0.60 0.006 0.229 0.014  -0.95 -0.78 
Ferrochelatase, mitochondrial 
(TMT) 
-1.17 -0.04 -0.71 0.005 0.751 0.011  -0.33 -1.54 
Leucine zipper protein 1 (TMT) -1.73 -0.20 -1.24 <0.001 0.267 0.006  0.85 -0.20 
Moesin (TMT) -1.15 -0.09 -0.79 0.003 0.543 0.006  -0.85 -1.06 
Non-histone chromosomal 
protein HMG-14 (TMT) 
-1.28 -0.20 -0.85 0.007 0.247 0.006  -0.81 -0.66 
Protein NDRG1 (TMT) -1.55 -0.41 -1.18 0.010 0.098 0.004  -0.17 -0.67 
825 
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Figure Legends 826 
Figure 1. Identification of APC-interacting and -regulated proteins. 827 
A Experimental Outline. Proteins in APC-containing complexes and changes in protein 828 
expression in response to siRNA-mediated depletion of APC and/or β-catenin were 829 
analyzed by label-free and TMT-based mass spectrometry. The overlap between the 830 
two data sets constitutes potential targets of alternative APC-containing complexes. B 831 
Proteins significantly enriched in C- and/or N-APC Co-IPs. Log2 fold change in mean 832 
LFQ intensities between N-APC Co-IP vs. control IP (x-axis) plotted against log2 fold 833 
change in mean LFQ intensities between C-APC Co-IP vs. control IP (y-axis, n=4 834 
experimental replicates). Significance determined by two-sided t-test with permutation-835 
based FDR <0.01 and s0 = 2 used for truncation (49). C GO, Pfam and KEGG terms 836 
significantly enriched in the APC interactome data set. Enrichment calculated by Fisher 837 
Exact Test, significance determined by Benjamini-Hochberg corrected FDR <0.02. 838 
Abbreviations: pos. - positive, reg. - regulation, comp.-med. - complex-mediated, nuc. - 839 
nucleation, organiz. - organization. 840 
 841 
Figure 2. APC interactome network. 842 
Network integrating known (blue), newly identified (orange), and indirect (grey) APC 843 
interaction partners. Nodes are labelled with corresponding gene names and node size 844 
correlates with degree of connectivity, i.e. number of edges. Components of distinct 845 
protein complexes (1, 3-5) and proteins associated with the cytoskeleton (2) cluster 846 
together in sub-networks. 847 
 848 
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Figure 3. β-catenin-dependent and –independent APC targets identified by TMT-label 849 
MS (A-D) and label-free MS (E-H). 850 
 851 
A/E Profiles of z-scored TMT (A) and LFQ (E) intensities of all measured proteins 852 
across samples. Protein identified as negative and positive β-catenin-independent APC 853 
targets are shown in orange and blue, respectively. Red lines show profiles for 854 
hypothetical ‘ideal’ targets that increase/decrease in response to APC depletion, but 855 
irrespective of a change in β-catenin. B/G Log2 fold change in mean TMT (B) and LFQ 856 
(G) intensities between APC siRNA and control siRNA treated samples (x-axis) plotted 857 
against the log2 fold change in mean intensities between β-catenin+APC siRNA and 858 
control siRNA treated samples (y-axis). Proteins selected based on their intensity 859 
profiles in A/E are shown in orange and blue, respectively. C and D Same as A, but for 860 
β-catenin-dependent APC targets.  861 
A Profiles of z-scored LFQ intensities of all measured proteins across samples. Protein 862 
identified as negative and positive β-catenin-independent APC targets are shown in 863 
orange and blue, respectively. Red lines show profiles for hypothetical ‘ideal’ targets 864 
that increase/decrease in response to APC depletion, but irrespective of change in β-865 
catenin levels.  B Log2 fold change in mean LFQ intensities between APC siRNA and 866 
control siRNA treated samples (x-axis) plotted against the log2 fold change in mean 867 
LFQ intensities between β-catenin+APC siRNA and control siRNA treated samples (y-868 
axis). Proteins selected based on their LFQ intensity profiles in A are shown in orange 869 
and blue, respectively. C and D Same as A, but showing β-catenin-dependent APC 870 
targets. 871 
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 872 
Figure 4. MINK1 binds to and is negatively regulated by APC. 873 
A Co-IP of MINK1 with full-length, endogenous APC in HeLa and U2OS cells. B Co-IP 874 
of MINK1 with C-terminally truncated APC in Colo320 and SW480 colorectal cancer 875 
cells; both cell lines lack the second WT allele. C Changes in MINK1 proteins levels in 876 
response to siRNA-mediated depletion of APC and/or β-catenin measured by WB. 877 
Shown are means and SD relative to control samples from four independent 878 
transfections. Significance relative to control determined by two-way ANOVA followed 879 
by Dunnett’s multiple comparison test; *: p value < 0.05, **: p value < 0.01. 880 
 881 
Figure 5. Mink1/Msn levels increase in response to Apc loss in vivo. 882 
A Expression of Mink1 in small intestinal tissue lysate from WT and ApcMin/+ mice 883 
measured by WB, each lane represents lysate obtained from individual mice. The 884 
ApcMin fragment of approximately 90 kDa was present in mutant mice, but full-length 885 
Apc (~310 kDa) was not detectable. B Quantification of WB shown in A. Shown is the 886 
mean WB signal across the four mice per genotype relative to the signal in WT mice 887 
and normalized to Gapdh. Significance relative to WT samples determined by un-888 
paired, two-tailed t test; p value: * < 0.05, ** < 0.01. C Live stage 8 Drosophila egg 889 
expressing NLS::RFP and PH::RFP (magenta) under the control of a ubiquitous 890 
promoter, and endogenous Msn::YFP (green). Two large APC1, APC2 double mutant 891 
clones within the follicular epithelium are identified by the absence of NLS::RFP and 892 
delimited by arrowheads. D Magnification of one APC1, APC2 double mutant clone 893 
displayed in C. E Intensity profiles of RFP and Msn::YFP signal along the follicular 894 
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epithelium. F Msn signal intensity at the interface between apc1-, apc2- / apc1+, 895 
apc2+ heterozygous cells (HT-ctrl, n=31), apc1+, apc2+ / apc1+, apc2+ homozygous 896 
control cells (HM-ctrl, n=31) and apc1-, apc2- / apc1-, apc2- homozygous mutant cells 897 
(HM-mut, n=38), normalized to the signal at heterozygous interfaces. In total ten clones 898 
from then different egg chambers were analyzed. Significance determined by two-tailed 899 
Mann-Whitney U test: p value: * = 0.0232, *** < 0.00001. 900 
 901 
Figure 6. MINK1 localizes to cell-cell junctions and its overexpression enhances cell 902 
adhesion.  903 
A mRNA expression of MINK1, CTNNB1, and AXIN2 measured by RT-qPCR 48 and 72 904 
h after siRNA transfection. Indicated are mean expression levels relative to ACTB 905 
expression with SD from four independent transfections. Significance determined by 906 
one-way ANOVA followed by Dunnett’s multiple comparison test; p value: * < 0.05, ** < 907 
0.01, *** < 0.001. Note, the same HeLa AXIN2 mRNA quantification data is also shown 908 
in Supplementary Figure S4D. B MINK1 protein levels in HeLa cells after treatment with 909 
neddylation inhibitor MLN4924 [3 µM] as measured by WB. Shown are relative mean 910 
signals normalized to DMSO-treated samples with SD from three independent 911 
experiments. Significance determined by one-way ANOVA, **: p value < 0.01. C Live 912 
imaging of HeLa SEC-C cells expressing endogenously mNeonGreen-tagged MINK1. 913 
Scale bars: 10 µm. D Adhesion assay with U2OS cells overexpressing MINK1-GFP and 914 
GFP, respectively. Adhesion to collagen matrix after one hour was quantified by staining 915 
of firmly attached cells with Crystal Violet. Indicated is mean absorbance with SD of 916 
independent experiments with two different GFP/MINK1-GFP clones and eight technical 917 
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replicates/condition. Significance determined by two-way ANOVA followed by Sidak’s 918 
multiple comparison test; p value: *** < 0.0003. E MTT proliferation assay in Colo320 919 
cells treated with siRNA against b-catenin or MINK1. Shown is the mean absorbance 920 
from triplicate measurements. Significance relative to control determined by one-way 921 
ANOVA followed by Dunnett’s multiple comparison test, p value: * < 0.05, ** < 0.01. 922 
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